The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

Russian mRNA cancer 'vaccine' shows promise in pre-clinical trials, part of growing immunotherapy trend in cancer treatment.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –– ...

Symptom scores remained stable over time, with similar QOL trends in both treatment arms.

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

Others have criticised ethical shortcomings in some pieces of clinical research on humans ... or the Northwick Park trial in 2006, where Phase I testing of a novel monoclonal antibody provoked ...

Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 First Quarter Conference Call. My name is Clint ...